A case of intrahepatic cholangiocarcinoma detected after successful interferon therapy for chronic hepatitis C

被引：1

作者：

Shinkawa H. ^{[1
]}

Hai S. ^{[2
]}

Tanaka H. ^{[2
]}

Takemura S. ^{[1
]}

Ohba K. ^{[1
]}

Uenishi T. ^{[1
]}

Kodai S. ^{[1
]}

Urata Y. ^{[1
]}

Kaneda K. ^{[1
]}

Sakae M. ^{[1
]}

Wakasa K. ^{[3
]}

Kubo S. ^{[1
]}

机构：

[1] Department of Hepato-Biliary-Pancreatic Surgery, Graduate School of Medicine, Osaka City University, Abeno-ku, Osaka 545-8585

[2] Department of Surgery, Higashisumiyoshi Morimoto Hospital, Osaka

[3] Department of Pathology, Osaka City University Hospital, Osaka

来源：

Clinical Journal of Gastroenterology | 2010年 / 3卷 / 1期

关键词：

Hepatitis C virus; Interferon therapy; Intrahepatic cholangiocarcinoma; Sustained virologic response;

D O I：

10.1007/s12328-009-0128-2

中图分类号：

学科分类号：

摘要：

A 65-year-old man presented at our hospital in 2006 because of a liver tumor. He had been treated for chronic hepatitis C with interferon-α2b for 6 months in 1998. A pathological examination showed that the hepatic tissue before interferon (IFN) therapy was classified as moderately active hepatitis with severe hepatic fibrosis. The IFN therapy induced the disappearance of the hepatitis C virus (HCV) RNA from his serum and normalized alanine aminotransferase activity. In 2005, a tumor (2 cm in diameter) was detected in the right lobe of the liver by ultrasonography and computed tomography, and the tumor was stained with contrast medium during abdominal angiography. A right lobectomy was performed under the diagnosis of hepatocellular carcinoma. The pathological examination revealed that the tumor was an intrahepatic cholangiocarcinoma (ICC). The noncancerous hepatic tissue was classified as having minimal activity with mild fibrosis. It is important to monitor closely for ICC as well as hepatocellular carcinoma even patients in whom the HCV RNA has disappeared after IFN therapy, because the outcome of treatment for small ICC is favorable. © 2009 Springer.

引用

页码：45 / 49

页数：4

共 26 条

[1] Tomimatsu M., Ishiguro N., Taniai M., Okuda H., Saito A., Obata H., Et al., Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular- cholangiocarcinoma) in Japan, Cancer, 72, pp. 683-688, (1993)
[2] Yamanaka N., Okamoto E., Ando T., Oriyama T., Fujimoto J., Furukawa K., Et al., Clinicopathologic spectrum of resected extraductal mass-forming intrahepatic cholangiocarcinoma, Cancer, 76, pp. 2449-2456, (1995)
[3] Yamamoto M., Takasaki K., Nakano M., Saito A., Minute nodular intrahepatic cholangiocarcinoma, Cancer, 82, 11, pp. 2145-2149, (1998)
[4] Kobayashi M., Ikeda K., Saitoh S., Suzuki F., Tsubota A., Suzuki Y., Arase Y., Murashima N., Chayama K., Kumada H., Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with Hepatitis C virus-related cirrhosis, Cancer, 88, 11, pp. 2471-2477, (2000)
[5] Yamamoto S., Kubo S., Hai S., Uenishi T., Yamamoto T., Shuto T., Takemura S., Tanaka H., Yamazaki O., Hirohashi K., Tanaka T., Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma, Cancer Science, 95, 7, pp. 592-595, (2004)
[6] Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., Et al., Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy, Ann Intern Med, 131, pp. 174-181, (1999)
[7] Toyoda H., Kumada T., Tokuda A., Horiguchi Y., Nakano H., Honda T., Et al., Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C, J Viral Hepat, 7, pp. 414-419, (2000)
[8] Kubo S., Nishiguchi S., Hirohashi K., Tanaka H., Tsukamoto T., Shuto T., Et al., Influence of previous interferon therapy on recurrence after resection of hepatitis C virus-related hepatocellular carcinoma, Jpn J Cancer Res, 92, pp. 59-66, (2001)
[9] Desmet V.J., Gerber M., Hoofnagle J.H., Manns M., Scheuer P.J., Classification of chronic hepatitis: Diagnosis, grading and staging, Hepatology, 19, pp. 1513-1520, (1994)
[10] Sorensen H.T., Friis S., Olsen J.H., Thulstrup A.M., Mellemkjaer L., Linet M., Trichopoulos D., Vilstrup H., Olsen J., Risk of liver and other types of cancer in patients with cirrhosis: A nationwide cohort study in Denmark, Hepatology, 28, 4, pp. 921-925, (1998)

← 1 2 3 →